A PUBLIC HEALTH ACTION PLAN TO COMBAT ANTIMICROBIAL RESISTANCE

PART 1: DOMESTIC ISSUES



### Interagency Task Force on Antimicrobial Resistance

Co

- chairs:

Centers for Disease Control and Prevention

Food and Drug Administration

National Institut es of Health

Agency for Healthcare Research and Quality

Health Care Financing Administration

Health Resources and Services Administration

Department of Agriculture

Department of Defense

Department of Veterans Affairs

Environmental Protection Agen cy1

A PUBLIC HEALTH ACTION PLAN TO COMBAT ANTIMICROBIAL RESISTANCE

PART 1: DOMESTIC ISSUES

TABLE OF CONTENTS

Executive Summary Page 2

Top Priority Action Items Page 7

Introduction and Overview Page 9

The Focus Areas

I. Surveillance (Action Items 1

- 20) Page 13

II. Prevention and Control (Action Items 21

- 66) Page 20

III. Research (Action Items 67

- 78) Page 32

IV. Product Development (Action Items 79

- 84) Page 37

References Page 412 A Public Health Action Plan to Combat Antimicrobial Resistance

Executive Summary

This Public Health Action Plan to Combat Antimicrobial Resistance ( Action Plan ) was developed by an interagency Task Force on Ant imicrobial Resistance that was created in 1999. The Task Force

is co

- chaired by the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health and also includes the Agency for Healthcare Research an d Quality, the Health Care Financing Administration, the Health Resources and Services Administration, the Department of Agriculture, the Department of Defense, the Department of Veterans Affairs, and the Environmental Protection Agency.

The Action Plan r eflects a broad

- based consensus of federal agencies on actions needed to address

antimicrobial

a resistance (AR). Input from state and local health agencies, universities, professional societies, pharmaceutical companies, health care delivery organizations , agricultural producers, consumer groups, and other members of the public was important in developing the plan. While some actions are already underway, complete implementation of this plan will require close collaboration with all of these partners, b a major objective of the process. The plan will be implemented incrementally, dependent on the availability of resources.

The Action Plan provides a blueprint for specific, coordinated federal actions to address the emerging

threat of antimicrobial resista nce. This document is Part I of the Action Plan , focusing on domestic issues. Since AR transcends national borders and requires a global approach to its prevention and control, Part II of the plan, to be developed subsequently, will identify actions that more specifically

address international issues. The Action Plan , Part I (Domestic Issues), includes four focus areas: Surveillance, Prevention and Control, Research, and Product Development. A summary of the top priority goals and action items in each f ocus area follows.

Surveillance

Unless AR problems are detected as they emerge

–and actions are taken quickly to contain them

–the

a In this document, the term “antimicrobial” is used inclusively to refer to any agent (including an

antibiotic ) used to kill or inhibit the growth of microorganisms (bacteria, viruses, fungi, or parasites.) This term applies whether the agent is intended for human, veterinary or agricultural applications.

b Implementation of this Action Plan requires working with a wide variety of partners, e.g. state and local health agencies, universities, professional societies, pharmaceutical and biotechnology companies, health care delivery organizations, insurers, agricultural producers, consumer groups, and the public. A

wide variety of expertise is needed, e.g., from clinicians, consumers, pharmacists, microbiologists, epidemiologists, behavioral and social scientists, economists, health policy researchers, and others. Partners and expertise needed will vary with different a ction items.3

world may soon be faced with previously treatable diseases that have again become untreatable, as in the pre

- antibiotic era. Priority Goals and Action Items in this focus area address ways to:

• Develop and implement a coordinated national plan for AR surveillance;

• Ensure the availability of reliable drug susceptibility data for surveillance;

• Monitor patterns of antimicrob ial drug use; and

• Monitor AR in agricultural settings to protect the public’s health by ensuring a safe food supply as well as animal and plant health.

A coordinated national surveillance plan for monitoring AR in microorganisms that pose a threat to publ ic health will be developed and implemented. The plan will specify activities to be conducted at national, state, and local levels; define the roles of participants; promote the use of standardized methods; and provide for timely dissemination of data to interested parties, e.g., public health officials, clinicians, and researchers. Needed core capacities at state and local levels will be defined and supported. When possible, the plan will coordinate, integrate, and build on existing disease surveillanc e infrastructure. All surveillance activities will be conducted with respect for patient and institutional confidentiality.

The availability of reliable drug susceptibility data is essential for AR surveillance. The accuracy of AR detection and reportin g will be improved through training and proficiency testing programs for diagnostic laboratories and by promoting and further refining standardized methods for detecting drug resistance in important pathogens, including bacteria, parasites, fungi, and viru ses. Public and private sector partners will address barriers to AR testing and reporting, e.g., barriers due to changes in health care delivery.

A plan to monitor patterns of antimicrobial drug use will be developed and implemented as an important compo nent of the national AR surveillance plan. This information is essential to interpret trends and variations in rates of AR, improve our understanding of the relationship between drug use and resistance, identify and anticipate gaps in availability of exis ting drugs, and identify interventions to prevent and control AR.

Improved surveillance for AR in agricultural settings will allow early detection of resistance trends in pathogens that pose a risk to animal and plant health, as well as in bacteria that e nter the food supply. Agricultural surveillance data will also help improve understanding of the relationship between antimicrobial drug and pesticide use and the emergence of drug resistance.

Prevention and Control

The prevention and control of drug

- re sistant infections requires measures to promote the appropriate

use c of antimicrobial drugs and prevent the transmission of infections (whether drug

- resistant or not).

c In this Action Plan , appropriate antimicrobial drug use is defined as use that maximizes therapeutic4

Priority Goals and Action Items in this focus area address ways to:

• Extend the useful life of antimicrobial drugs through appropriate use policies that discourage overuse and misuse;

• Improve diagnostic testing practices;

• Prevent infection transmission through improved infection control methods and use of vaccines;

• Prevent and control emergi ng AR problems in agriculture, human and veterinary medicine; and

• Ensure that comprehensive programs to prevent and control AR involve a wide variety of nonfederal partners and the public so these programs become a part of routine practice nationwide.

App ropriate drug

- use policies will be implemented through a public health education campaign on appropriate antimicrobial drug use as a national health priority. Other actions in support of appropriate drug use will include reducing inappropriate prescribing through development of clinical guidelines and
computer

- assisted decision support, considering regulatory changes, supporting other interventions promoting education and behavior change among clinicians, and informing consumers about the uses

and limitati ons of antimicrobial drugs.

Improved diagnostic practices will be promoted by encouraging the use of rapid diagnostic methods to guide drug prescribing, facilitating direct consultation between clinicians and laboratory personnel with appropriate expertis e and authority, and promoting the use of appropriate laboratory testing methods. Guidelines, training, and regulatory and reimbursement policies will be utilized to promote improved diagnostic practices.

Reduced rates of infection transmission will be a ddressed through public health campaigns that promote vaccination and hygienic practices such as hand washing, safe food handling, and other behaviors associated with prevention of infection transmission. Infection control in health care settings

will be enhanced by developing new interventions based on rapid diagnosis, improved understanding of the factors that promote cross

- infection, and modified medical devices or procedures that reduce the

risk of infection.

The prevention and control of AR in agricu lture and veterinary medicine requires 1) improved understanding of the risks and benefits of antimicrobial use and ways to prevent the emergence and spread of resistance; 2) development and implementation of principles for appropriate antimicrobial drug u se in the production of food animals and plants; 3) improved animal husbandry and food

production practices to reduce the spread of infection; and 4) a regulatory framework to address the need for antimicrobial drug use in agriculture and veterinary medici ne while ensuring that such use does not pose a risk to human health.

impact while minimizing toxicity and the development of resistance. In practice, this means prescribing antimicrobial therapy when and only when beneficial to a patient; targeting therapy to the desired pathogens; and using the appropriate drug, dose, and duration.5

Comprehensive, multifaceted programs involving a wide variety of nonfederal partners and the public are required to prevent and control AR. The AR Task Force agencies will ensure ongoi ng input from, review by, and collaboration with nonfederal partners. The appropriate agencies will support demonstration projects that use multiple interventions to prevent and control AR (e.g., through surveillance, appropriate drug use, optimized diagn ostic testing, immunization practice, and infection control). The Task Force agencies will encourage the incorporation of effective programs into routine practice by implementing model programs in federal health care systems and promoting the inclusion of AR prevention and control activities as part of quality assurance and accreditation standards for health care delivery nationwide.

Research

Understanding the fundamental processes involved in antimicrobial resistance within microbes and the resulting im

pact on humans, animals, and the environment forms an important basis for influencing and changing these processes and outcomes. Basic and clinical research provides the fundamental knowledge necessary to develop appropriate responses to antimicrobial res istance emerging and spreading in hospitals, communities, farms, and the food supply. Priority Goals and Action Items in this focus area address ways to:

• Increase understanding of microbial physiology, ecology, genetics and mechanisms of resistance;

• Augm ent the existing research infrastructure to support a critical mass of researchers in AR and related fields; and

• Translate research findings into clinically useful products, such as novel approaches to detecting, preventing, and treating antimicrobial resi stant infections.

Needs in the field of AR research will be identified and addressed through a government

- wide program review with external input. Additional research is needed, for example, on the epidemiology of resistance genes; on mechanisms of AR em ergence, acquisition, spread, and persistence; and on the effects of antibiotics used as agricultural growth promotants on microbes that live in animals, humans, plants, soil and water. Further study is also required to determine whether variations in dru g use regimens may stimulate or reduce AR emergence and spread. Improved understanding of the causes of AR emergence will lead to the development of tools for reducing microbial resistance, as well as for predicting where AR problems are likely to arise.

A comprehensive research infrastructure will help ensure a critical mass of AR researchers who will interact, exchange information, and stimulate new discoveries. This aim will be achieved through the appropriate strategies and scientific conferences tha t promote research on AR. The AR Task Force agencies will work with the academic and industrial research communities to attract AR researchers, prioritize needs, identify key opportunities, and optimize the utilization of resources to address AR problems.6

The translation of research findings into innovative clinical products to treat, prevent, or diagnose drug

- resistant infections is an area in which the federal government can play an important role, focusing on gaps not filled by the pharmaceutical indus try or by other nongovernment groups. Special efforts will be placed on the identification, development and testing of rapid, inexpensive, point

- of

- care diagnostic methods to facilitate appropriate use of antimicrobials. The AR Task Force agencies will

a lso encourage basic research and clinical testing of diagnostic methods, novel treatment approaches, new vaccines, and other prevention approaches for resistant infections.

Product Development

As antimicrobial drugs lose their effectiveness, new product s must be developed to prevent, rapidly diagnose, and treat infections. The Priority Goals and Action Items in this focus area address ways to:

• Ensure that researchers and drug manufacturers are informed of current and projected gaps in the

arsenal of an

timicrobial drugs, vaccines, and diagnostics and of potential markets for these products (designated here as “AR products”);

• Stimulate the development of priority AR products for which market incentives are inadequate, while fostering their appropriate use ; and

• Optimize the development and use of veterinary drugs and related agricultural products that reduce the transfer of resistance to pathogens that can infect humans.

Current and projected gaps in the arsenal of AR products and potential markets for the se products will be reported to researchers and drug manufacturers through an interagency working group convened to identify and publicize priority public health needs.

The development of urgently needed AR products will be stimulated throughout the proce ss from drug discovery through licensing. The regulatory process for AR products will continue to be streamlined, and incentives that promote the production and appropriate use of priority AR products can be evaluated in pilot programs that monitor costs and assess the return on the public investment.

The production of veterinary AR products that reduce the risk of development and transfer of resistance to drugs used in human clinical medicine will be expedited through a streamlined regulatory and approva l process. As with drugs for the treatment of human infections, pilot programs can be initiated to evaluate incentives that encourage the development and appropriate use of priority products that meet critical animal and plant health needs.

Private and p ublic partners will also evaluate ways to improve or reduce the agricultural use of particular antimicrobial drugs, as well as ways to prevent infection, such as the use of veterinary vaccines, changes in animal husbandry, and the use of competitive exclus ion products (i.e., treatments that affect the intestinal flora of food animals).7 Top Priority Action Items to Combat Antimicrobial Resistance (All 13 items have top priority, regardless of their order in the list)

Surveillance

• With partners, design an d implement a national AR surveillance plan that defines national, regional, state, and local surveillance activities and the roles of clinical, reference, public health, and veterinary laboratories. The plan should be consistent with local and national su rveillance methodology and infrastructure that currently exist or are being developed. (Action Item #2)

• Develop and implement procedures for monitoring patterns of antimicrobial drug use in human medicine, agriculture, veterinary medicine, and consumer pr oducts. (Action Item #5)

Prevention and Control

• Conduct a public health education campaign to promote appropriate antimicrobial use as a national health priority. (Action Item #25)

• In collaboration with many partners, develop and facilitate the implemen tation of educational and behavioral interventions that will assist clinicians in appropriate antimicrobial prescribing. (Action Item #26)

• Evaluate the effectiveness (including cost

- effectiveness) of current and novel infection

- control practices for heal

th care and extended care settings and in the community. Promote adherence to practices proven to be effective. (Action Item #39)

• In consultation with stakeholders, refine and implement the proposed FDA framework for approving new antimicrobial drugs for use in food

- animal production and, when appropriate, for re

evaluating currently approved veterinary antimicrobial drugs. (Action Item #58)

• Support demonstration projects to evaluate comprehensive strategies that use multiple interventions
to promote app ropriate drug use and reduce infection rates, in order to assess how interventions found effective in research studies can be applied routinely and most cost

- effectively on a large

scale. (Action Item #63)

Research

• Provide the research community genomics and other powerful technologies to identify targets in critical areas for the development of new rapid diagnostics methodologies, novel therapeutics,8

and interventions to prevent the emergence and spread of resistant pathogens. (Action Item #70)

• In cons ultation with academia and the private sector, identify and conduct human clinical studies addressing AR issues of public health significance that are unlikely to be studied in the private sector (e.g., novel therapies, new treatment regimens, and other pr oducts and practices). (Action Item #75)

• Identify, develop, test, and evaluate new rapid diagnostic methods for human and veterinary uses with partners, including academia and the private sector. Such methods should be accurate, affordable, and easily implemented in routine clinical settings (e.g., tests for resistance genes, point

- of

- care diagnostics for patients with respiratory infections and syndromes, and diagnostics for drug resistance in microbial pathogens, including in nonculture specimens). (A ction Item #76)

• Encourage basic and clinical research in support of the development and appropriate use of vaccines in human and veterinary medicine in partnership with academia and the private sector. (Action Item #77)

Product Development

• Create an Inte ragency AR Product Development Working Group to identify and publicize priority public health needs in human and animal medicine for new AR products (e.g., innovative drugs, targeted spectrum antibiotics, point

- of

- care diagnostics, vaccines and other biolo gics,

anti

- infective medical devices, and disinfectants). (Action Item #79)

• Identify ways (e.g. financial and/or other incentives or investments) to promote the development and/or appropriate use of priority AR products, such as novel compounds and approa ches, for human and veterinary medicine for which market incentives are inadequate. (Action Item #80)9 Introduction and Overview

Background

In the 1940s, the widespread availability of penicillin and the subsequent discovery of streptomycin led

to a d ramatic reduction in illness and death from infectious diseases. However, bacteria and other

disease

- causing organisms

–viruses, fungi, and parasites

–have a remarkable ability to mutate and acquire resistance genes from other organisms and thereby deve lop resistance to antimicrobial drugs. When an antimicrobial drug is used, the selective pressure exerted by the drug favors the growth of organisms that are resistant to the drug’s action. The extensive use of antimicrobial drugs has resulted in drug re sistance that threatens to reverse the miracles of the last half century.

Drug

- resistant pathogens are a growing menace to all people, regardless of age, gender, or socioeconomic background. They endanger people in affluent, industrial societies like the United States, as well as in less developed nations. Examples of clinically important microbes that are rapidly developing resistance to available antimicrobials include bacteria that cause pneumonia, ear infections, and meningitis (e.g., Streptococcus p neumoniae 1 ), skin, bone, lung, and bloodstream infections (e.g., Staphylococcus aureus 2 ,3 ), urinary tract infections (e.g., Escherichia coli 4 ), foodborne infections (e.g.,

Salmonella 5 ), and infections transmitted in health care settings (e.g., enterococci 6 and Klebsiella spp. 7 ).

For example, up to 30 percent of S. pneumoniae found in some areas of the United States are no longer susceptible to penicillin, and multidrug resistance is common. Approximately 11 percent of S. pneumoniae are resistant to “third generation” cephalosporin antibiotics, and resistance to the newest fluoroquinolone antimicrobials has already been reported. 8 Nearly all strains of Staphylococcus aureus in the United States are resistant to penicillin, and many are resistant to newer m ethicillin

- related drugs. 2
Since 1997, strains of S. aureus with decreased susceptibility to vancomycin, for many years the only uniformly effective treatment, have been reported. 9,10

Many other pathogens

–including the bacteria that cause tuberculosis 1 1 and gonorrhea, 12 human immunodeficiency virus, 13 the fungi that cause yeast infections, 14 and the parasites that cause malaria 15

– are also becoming resistant to standard therapies. If we do not act to address the problem of AR, we may lose quick and re liable treatment of infections that have been a manageable problem in the United States since the 1940s. Drug choices for the treatment of common infections will become increasingly limited and expensive

–and, in some cases, nonexistent.

Risk While anyo ne may acquire a drug

- resistant infection, certain people are at increased risk, e.g., patients in hospitals and children in daycare centers. Drug

- resistant infections may be acquired in health care settings (e.g., staphylococcal infections in intensive c are units), in the community (e.g. pneumococci acquired from a classmate) and through the food supply (e.g., salmonella acquired from meat or eggs), both domestically and overseas. However, resistant microbes are increasingly appearing in new settings. M ethicillin

- resistant S. aureus , which for 30 years with few exceptions was a problem only in10

hospitals, is now occurring in the community. 3,16

Costs The costs of treating AR infections place a significant burden on society

–a burden that is likely to gro w larger as the number of cases of drug

- resistant illness increase. Individuals infected with drug resistant organisms are more likely to require hospitalization, to remain in the hospital for a longer time, and to have a poor prognosis. For example, it has been estimated that the in

- hospital cost of hospital

- acquired infections caused by just six common kinds of resistant bacteria are at least $1.3 billion per year, in

1992 dollars. 17 This estimate does not include the costs of infections caused by other pathogens, the costs of lost workdays, post

- hospital care, or resistant infections in the outpatient or extended care facility settings.

Solutions AR will always be with us. The challenge before us is to transform this increasingly urgent threat into a manageable problem. Over the past ten years, the Institute of Medicine, 18 the American Society for Microbiology, 19 World Health Organization 20 other panels of distinguished experts, the Congressional Office of Technology Assessment, 17 and the General Acco unting Office 21, 22 have provided recommendations and options for government action to address the dangers posed by AR. The experts agree that we need to improve surveillance for emerging AR problems, to prolong the useful life of antimicrobial drugs, to

develop new drugs, and to utilize other measures, e.g., improved vaccines, diagnostics, and infection control measures to prevent and control AR.

Despite the urgency of the problem, the achievement of these goals has not been simple or straightforward, a

nd accomplishments to date have been insufficient. Monitoring, preventing, and controlling AR requires sustained effort, commitment, and collaboration among many groups in the public and private sectors, and involvement of the general public. It also req uires support and leadership from the federal government and a willingness to address complex and sometimes controversial scientific, medical, and economic issues.

A Public Health Action Plan to Combat Antimicrobial Resistance

A Public Health Action Plan to Combat Antimicrobial Resistance provides a blueprint for specific, coordinated federal government actions to address this emerging threat. The plan builds upon reports prepared by expert panels in recent years. This document is Part I of the plan, fo cusing on domestic issues. However, AR transcends national borders and requires a global approach to its prevention and control. Part II of the plan, to be developed after the World Health Organization finalizes its Global Strategy for the Containment of Antimicrobial Resistance, 23 will identify federal actions that more specifically address international issues with input from and in collaboration with WHO and additional
partners. A National Action Plan to Combat Multi

- drug Resistant Tuberculosis has be en published previously. 24

Plan Development11

This plan was developed by an Interagency Task Force on Antimicrobial Resistance that was created in
1999. The Task Force is co

- chaired by the Centers for Disease Control and Prevention (CDC), the

Food and Dru

g Administration (FDA), and the National Institutes of Health (NIH), and also includes the Agency for Healthcare Research and Quality (AHRQ), the Health Care Financing Administration (HCFA), the Health Resources and Services Administration (HRSA), the Depa rtment of Agriculture (USDA), the Department of Defense (DoD), the Department of Veterans Affairs (DVA), and the Environmental Protection Agency (EPA).

The plan is based in part on input obtained at a public meeting held in Atlanta, Georgia, in July 1999. 25
Present at the public meeting were consultants from a wide variety of groups, including state and local health agencies, universities, professional societies, pharmaceutical and biotechnology companies, health care delivery organizations, agricultural producers, consumer groups, and the public. A draft of the plan was released for public comment in June 2000, 26 and the plan was modified following consideration of

comments received.

Partnerships, Implementation, and Coordination The plan reflects a br

oadly

- based consensus of federal agencies on federal actions to combat AR. However, implementation of this plan will require collaboration with many partners. b More specific details of these collaborations will be developed by the agencies as the actions are implemented.

The plan will be implemented incrementally as resources become available. The agencies recognize that a number of the items may require either new statutory authority or changes in regulatory requirements.

The extent to which such meas ures may be needed to implement a given action item will be considered by the agencies involved.

The plan includes a summary and a list of issues, goals, and action items addressing surveillance, prevention and control, research, and product development. d For each action item, coordinator and collaborator agencies/departments are specified. Contingent on available resources, the coordinators will assume the primary responsibility of carrying out the specified action items and the collaborators will

assis t and/or carry out part of the specified action. Additional agencies may become collaborators in

the future.

The Task Force identified 13 top priority action items. Approximate timelines were also identified for all action items; these timelines prov ide another indication of priority but also take into account prerequisites for certain items and the achievable pace of action on sometimes complex issues. Designation of top priorities and timelines was a difficult task given the realization that many i tems could be considered top priority and should ideally begin immediately. For action items with multiple

d Except where specified, these issues, goals, and action items apply to human AR issues and not to nonhuman (e.g., agricultural) i ssues. Agricultural issues refer to the production of animals and plants, as well as fish and other species (aquaculture).12

component parts, the agencies involved will further develop priorities and timelines, with appropriate input from outside partners, as they implemen t the action item.

The Interagency Task Force will continue to facilitate coordination among agencies and monitor implementation of the plan. During the coming years, the Task Force will publish periodic reports detailing how the plan is being implemente d, solicit comments from the public,

–and if necessary, update the plan. Details of current agency activities regarding AR are beyond the scope of this document, but may be obtained by contacting the specific agencies.13 The Focus Areas

I. Surveillance

Su rveillance of AR is critical to providing early warning of emerging problems, monitoring changing patterns of resistance, and targeting and evaluating prevention and control measures. e Timely surveillance information is also necessary for assisting resear chers in developing new drugs and for providing good patient care. For example, clinicians should be informed of drug resistance problems in their communities that may influence their prescribing decisions in order to help them avoid treatment

failures. In addition, monitoring patterns of antimicrobial drug use is needed to interpret trends and variations in rates of AR, improve understanding of the relationship between drug use and resistance, identify and anticipate gaps in availability of existing drug s, and help identify preventive interventions.

At present, the United States lacks a coordinated national plan for AR surveillance. Creating a national plan requires collaboration with partners in the public and private sectors. Improved AR surveillance depends on enhancing epidemiologic and laboratory capabilities at local, state, and national levels; using standardized and reliable laboratory testing methods; and enhancing use of informatics.

A. Issue: The United States lacks a coordinated national plan for surveillance of:

• AR emergence in organism

- drug combinations of public health importance and

• Antimicrobial drug use in human and nonhuman settings.

1. Goal: Collaborate with appropriate partners to develop procedures and methods for

surveillance

of AR emergence in organism

- drug combinations of public health importance.

a. Action Items

(1) Determine which organisms and susceptibility to specific antimicrobial drugs should be under surveillance and create a mechanism for pe riodic updating of this list. Coordinators: CDC, FDA, USDA, EPA

Timeline: Initiated

(2) TOP PRIORITY ACTION ITEM

- With partners, design and implement a national

e Public health surveillance is the ongoing, systematic collection, analysis, and interpretation of data for use in the planning, imp lementation, and evaluation of public health practice. Desirable qualities of any system include simplicity, flexibility, acceptability, sensitivity, and representativeness. A surveillance system also includes the time ly dissemination of these data to pe rsons who can undertake effective prevention and control activities, including clinicians, researchers, laboratorians, and public health personnel. (MMWR, Guidelines for Evaluating Surveillance Systems, May 6, 1988/37(S5); 118.)14 AR surveillance plan:

• Identify the components of a national AR surveillance plan a nd the roles of partners in its design and implementation. Coordinator: CDC; Collaborators: DoD, DVA, FDA, USDA, HCFA

• Determine which surveillance activities should be conducted routinely at national, regional, state, or local levels and which may require specialized projects. Coordinators: CDC, FDA, USDA

• Define the roles of clinical, reference, public health, and veterinary laboratories at federal, state, and local levels in AR surveillance. Coordinator: CDC; Collaborators: DoD, DVA, FDA, USDA, HCFA

• Improve coordination of AR surveillance systems at CDC, FDA, and USDA (e.g., identify components for integration). Coordinators: CDC, FDA, USDA

• Consider the role of nongovernment funded surveillance and other data collection systems to augment a national surveillance plan. Coordinators: CDC, FDA, USDA

• Ensure that the national AR surveillance plan is consistent with local and national surveillance methodology and infrastructure that currently exist or are being developed.

Coordinators: CDC, USDA, FDA

• Identi fy and assess practical surveillance strategies for components of the national plan by conducting pilot studies and demonstration projects. Coordinators: CDC, USDA, FDA Timeline for entire action item 2: Begin within one to two years

(3) Develop standa

rds and methodologies.

• Develop standards and methodologies for monitoring drug

- resistant microbes in humans, animals, and plants as well as for monitoring drug

- resistant microbes in food products and environmental samples.

Coordinators: CDC, UDSA, FDA, EPA

• Develop standardized laboratory methodologies and data elements that allow susceptibility test results and AR surveillance data to be compared across geographic jurisdictions.

Coordinators: CDC, USDA, FDA, EPA

• Explore the use of standardized d efinitions and methodology (Related Action Item: Surveillance #5) to create an electronic surveillance system health care institutions can use to compare AR data from other local facilities. Coordinator: CDC; Collaborators: HCFA, DVA, DoD, HRSA

• Encourage d evelopment of local, regional, and national data systems that allow linking of microbiology, clinical and pharmaceutical data that would support local decision making for prevention and control of antimicrobial resistance and15 facilitate surveillance for an timicrobial resistance at all levels. Coordinator: CDC; Collaborators: HCFA, DVA, DoD, HRSA

• Develop standards for reporting quantitative resistance data (e.g., minimal inhibitory concentrations or zone diameters) in ways that will detect decreased suscepti bility. These standards are necessary because numerical AR test results reported nonquantitatively (e.g., as susceptible, intermediate, or resistant) as “susceptible” may mask an emerging AR problem, i.e, microbes with a small decrease in susceptibility m ay still be classified as susceptible. Coordinators: CDC, USDA, FDA

• Assess how current policies on maintaining the confidentiality of medical and veterinary data collected for other purposes relate to procedures for gathering

data on antimicrobial resista nce. If necessary, develop a comprehensive national confidentiality policy on human and agricultural AR surveillance that includes both patient and institutional confidentiality, is consistent with confidentiality policies applied to other forms of survei llance and research data, and recognizes the differences in human and animal medicine and food production surveillance programs. Coordinator: CDC; Collaborators: DVA, HCFA, DoD, FDA, USDA Timeline for entire action item 3: Initiated

(4) Address additional sur veillance issues unique to AR.

• Conduct post

- marketing surveillance for the development of resistance to critical antimicrobial drugs. Surveillance should be linked to information on drug use, and criteria should be developed to allow a prompt response to a finding of increased resistance associated with a specific pattern of use (e.g., consumer and professional alerts, enhanced education, labeling changes, or restrictions on use depending on the extent of and reasons for emergence of resistance).

Coordinat ors: FDA, CDC, USDA

• Facilitate the collection of AR surveillance data on pathogens for which cultures are not routinely obtained, either because the infections are empirically treated without laboratory diagnosis or because they are diagnosed with noncultu re

tests.
Coordinator: CDC

• Enhance availability of isolates of drug

- resistant microbes to researchers (e.g., via a network of collections with an accessible databank). Coordinator: CDC; Collaborator: NIH Timeline for entire action item 4: Begin within one to two years16

2. Goal: Collaborate with appropriate partners to develop procedures and methods for nationwide surveillance of antimicrobial drug use in human and nonhuman settings.

a. Action Items

(5) TOP PRIORITY ACTION ITEM

- Develop and implemen t procedures for monitoring antimicrobial use in human medicine, agriculture, veterinary medicine, and consumer products:

• Link human drug

- use data to clinical information (e.g., diagnosis, severity of illness, and outcome).

• Link agricultural drug

- use data to species and usage patterns.

• Assess potential effects of geographic variations in drug use on the incidence and prevalence of antimicrobial resistance.

• Incorporate appropriate confidentiality protections.

• Identify and anticipate gaps in availability of e xisting drugs. (Related Action Item: Product Development #79). Coordinators: CDC, FDA, USDA; Collaborators: EPA, DVA, DoD Timeline for entire action item 5: Begin within one to two years

(6) Identify and evaluate methods for collecting (e.g., optimal sa mpling methods) and disseminating the surveillance data on antimicrobial drug use:

• Identify inexpensive sources of drug use data (e.g., the National Ambulatory Medical Care Survey [NAMCS], the National Hospital Ambulatory Medical Care Survey [NHAMCS], and databases in some health care delivery systems and pharmacies) and evaluate their usefulness for surveillance purposes Coordinators: CDC, FDA

• Consider ways that results of periodic drug use surveys could be made available to food animal producers and veterinarians to encourage participation in data

collection Coordinators: CDC, FDA, USDA Timeline for entire action item 6: Begin within one to two years

(7) Work with accrediting agencies to address antimicrobial drug

- use monitoring as part of quality assur ance in health care delivery systems. (Related Action Item: Prevention and Control #64)

Coordinators: CDC, HCFA Timeline: Begin within one to two years

B. Issue: Implementation of the national plan for AR surveillance will require:

• Reliable drug suscept

ibility data;

• Adequate capacity and resources at state and local health and agricultural agencies; and17 • An accessible, centralized source of AR data.

1. Goal: Promote the consistent and appropriate use of reliable laboratory tests for

antimicrobial drug s usceptibility.

a. Action Items

(8) Ensure that clinical laboratories that provide data for AR surveillance purposes have access to and routinely participate in pertinent training and proficiency testing programs with good performance and indicate AR testin g methodologies in their surveillance reports (e.g., specific automated methods or manual techniques). Coordinator: CDC; Collaborator: HCFA

Timeline: Initiated

(9) Evaluate the performance of licensed, automated AR testing devices in the context of

chan ging resistance patterns and update their labeling where appropriate (e.g., changes in quantitative resistance that may make a test result invalid). Coordinators: FDA, CDC

Timeline: Initiated

(10) Working with partners, b including the National Committee for Clinical Laboratory Standards (NCCLS), further develop, refine, and promote standardized clinical, epidemiologic, and laboratory methods for documenting and assessing the significance of drug resistance among yeasts and moulds, parasites, and viruses

C oordinators: CDC, NIH, FDA, USDA, HCFA

Timeline: Initiated

(11) Identify ways to overcome economic, legal, and other barriers to appropriate AR testing and to the reporting of results (e.g., sufficient human resources, cost considerations, empiric treatm ent recommendations, managed

- care practices, etc.). (Related Action Item: Prevention and Control #34) Coordinators: HCFA, HRSA, CDC, AHRQ Timeline: Begin within one to two years

(12) Pursue legal mechanisms for manufacturers to provide otherwise unavaila ble drugs to government reference laboratories for the sole purpose of antimicrobial drug susceptibility testing (as part of surveillance) with the understanding that these drugs will not be used for drug discovery purposes.

Coordinator: CDC Timeline: Begi n within one to two years

2. Goal: Ensure that state and local health and agricultural agencies have the capacity to18 conduct surveillance of drug

- resistant organisms of public health importance.

a. Action Items

(13) With state health and agriculture depart ments and other stakeholders, define needed core capacity (the minimum needed in human, laboratory, and electronic resources)

at the state and local level to ensure that basic AR surveillance is conducted in these jurisdictions. As part of this effort, en sure that state public health and veterinary diagnostic laboratories maintain the capacity to test the drug

- susceptibility patterns of resistant organisms of public health importance, especially for drug

microorganism combinations for which testing methods are not routinely available at hospital and commercial laboratories. Coordinators: CDC, USDA, FDA Timeline: Begin within one to two years

(14) Provide resources to assist in meeting state and local core capacity needs for AR surveillance. Strive to prov ide consistent funding from year to year to state and local public health and veterinary diagnostic laboratories that meet quality assurance

standards.

Coordinators: CDC, USDA
Timeline: Initiated

3. Goal: Disseminate surveillance data in a timely manner t o public health officials, clinicians, and others who may make decisions based on an analysis of the data.

a. Action Items

(15) Provide an accessible, centralized source of AR data from major surveillance systems involving animal and human populations. In consultation with stakeholders, determine how to report AR data in a way that is valid and useful to interested parties (e.g., clinicians, public health officials, veterinarians, and researchers). Include sufficient detail in surveillance reports to permi t local analysis and comparison with trends in drug use and medical and agricultural practices. Coordinators: CDC, USDA, FDA, HCFA Timeline: Begin within one to two years

(16) Provide health care system administrators and other decision makers with data o n the impact of drug

- resistant organisms (e.g., outcome, treatment costs) and on effective prevention and control measures. Coordinators: CDC, AHRQ Timeline: Begin within one to two years19

C. Issue: Monitoring AR in agricultural settings is essential to en sure animal and plant health and a safe food supply.

1. Goal: Monitor AR in animal and plant pathogens and in bacteria that can be transmitted to

humans through the food supply.

a. Action Items

(17) Expand and enhance coordination of surveillance for drug

- resistance in enteric bacteria in sick and healthy humans and in sick and healthy animals on farms, at slaughter, and at retail. This effort includes:

• Expanding the National Antimicrobial Resistance Monitoring System: Enteric Bacteria (NARMS:EB);

• Compari

ng AR data on pathogenic and nonpathogenic organisms detected on farms (in sick and healthy animals), at slaughter, and in commercial food products; and

• Utilizing these data to monitor the transmission of resistant infections and assess

the effectiveness o f prevention measures

Coordinators: CDC, FDA, USDA
Timeline: Initiated

(18) Evaluate the usefulness of monitoring sentinel human populations (e.g., farm, abattoir, fruit and vegetable, and food processing plant workers) and persons in the general communi

ty for infection or colonization with resistant enteric bacteria. Coordinators: CDC, USDA, FDA Timeline: Begin within three to five years

(19) Conduct pilot studies to assess the extent of environmental contamination by antimicrobial drug residues and dru g

- resistant organisms that enter the soil or water from human and animal waste. If contamination is detected, conduct appropriate surveillance in waste, surface and ground water, and soil from agricultural areas in which waste is used for fertilizer, and conduct studies to determine potential impact on human and animal health. (Related Action Item: Prevention and Control #55) Coordinators: EPA, CDC, USDA

Timeline : Initiated

(20) Gather information on the relationship between antimicrobial pesticide and herbicide use and the emergence of drug

- resistance by monitoring:

• The prevalence and incidence of drug

- resistant organisms in agricultural areas where antimicrobial pesticides are used and areas where they are not used, and

• The prevalence of colonization or infection with resistant bacteria in human or animal populations who live or work near orchards or who consume fruit20 products sprayed (or treated) with antimicrobial. pesticides (Related Action Item: Prevention and Control #62) Coordinators: EPA, CDC, USDA Timeline: Begin within three to five years

II. Prevention and Control

Prevention and control of drug

- resistant infections require measures to promote the appropriate use of antimicrobial drugs and prevent infection transmission. The concept of app ropriate use may be expressed in various other ways, e.g., good antimicrobial stewardship or judicious, prudent, or rational

use. In this Action Plan , appropriate antimicrobial drug use is defined as use that maximizes therapeutic impact while minimizing toxicity and the development of resistance. In practice, this means prescribing antimicrobial therapy when and only when beneficial to a patient; targeting therapy to the desired pathogens; and using the appropriate drug, dose, and duration. Appropriate an timicrobial drug use should not be interpreted simply as reduced use because these drugs offer valuable benefits when used appropriately. It is overuse and misuse that must be decreased to reduce the selective pressure favoring the spread of resistance.

Appropriate use can be facilitated in various ways, e.g., by promoting informed prescribing by clinicians, informing consumers about the proper use and limitations of antimicrobial drugs, and improving diagnostic techniques. The challenge facing public h ealth organizations is to work with partners to identify effective methods of promoting appropriate antimicrobial drug use and to translate these interventions into routine medical practice.

Measures to prevent infection transmission, whether drug

- resist ant or not, are also very important in controlling AR. These measures include the appropriate use of vaccines and infection control, sanitation, hygiene measures, and other safe behaviors, e.g., safe sexual practices. Efforts to control drug

- resistant in

fections must become part of everyday practice in health care settings across the nation, as well as in other settings (e.g., agriculture and veterinary medicine) in which antimicrobial drugs are used. Partners in many sectors of society and the general p ublic will need to be involved in this effort.

A. Issue: Appropriate use of antimicrobial drugs can offer great benefits to patients, but overuse and misuse of these drugs can hasten the development of resistance and shorten the drug’s

useful life.

1. Goal: Id entify effective methods for promoting appropriate antimicrobial use.

a. Action Items

(21) Identify factors that promote or impede appropriate drug use in hospitals, extended care facilities, and outpatient settings in collaboration with partners. b

Coor dinator: CDC; Collaborators: FDA, AHRQ, DVA, DoD21 Timeline: Initiated

(22) Develop appropriate drug use policies and evaluate the impact (including on prescribing patterns, resistance rates, patient outcome, and cost) of implementing these policies in hosp itals and other health care delivery settings. Identify ways to increase adherence to appropriate use policies proven to be beneficial in collaboration with partners. b
Coordinator: CDC; Collaborators: AHRQ, FDA, DVA, DoD, HCFA

Timeline: Initiated

(23) Ev aluate the relationship between prescribing behavior and specific antimicrobial drug marketing and promotional practices. Assess the public health effects of these practices in collaboration with partners. b

Coordinators: CDC, FDA Timeline: Begin within th ree to five years

(24) Help individual hospitals and health care systems analyze how the availability of AR data and computer

- assisted decision support systems influences prescriber behavior, health outcomes, and costs. This plan may include the provisio n of computer software and the establishment of projects that involve the Medicare Peer Review Organizations (PROs). Coordinator: CDC; Collaborators: HCFA, DVA, DoD Timeline: Begin within three to five years

2. Goal: Promote appropriate antimicrobial use through educational and behavioral

interventions found to be effective.

a. Action Items

(25) TOP PRIORITY ACTION ITEM

- Conduct a public health education campaign to promote appropriate antimicrobial use as a national health priority. The campaign should involve many partners. b Elements of this campaign may include:

• Culturally appropriate educational and behavioral interventions implemented through community

- based programs that target patients and selected populations and communities, such as daycare cen ters and schools;

• Strategies to improve patient adherence to appropriate therapies;

• A clearinghouse for educational materials (e.g., booklets and CD

- ROM presentations) on appropriate drug use and AR prevention;

• A periodically updated priority list of drug

- resistant microorganisms in humans and animals; and

• A glossary disseminated through CDC Website that defines technical words commonly used in discussions of AR issues.22 Coordinators: CDC, FDA; Collaborators: USDA, HCFA Timeline: Begin within one to two year s

(26) TOP PRIORITY ACTION ITEM

- In collaboration with many partners, b
develop and facilitate the implementation of educational and behavioral interventions that will assist clinicians in appropriate antimicrobial prescribing. Examples may

include:

• Educ ational curricula and training modules for all prescribing clinicians, health professions students, trainees, and senior health care administrators as part of quality assurance programs;

• Clinical guidelines that address appropriate antimicrobial use;

• Infor matics technology (e.g., computer

- assisted decision support) to assist in point

- of

- care prescribing and patient outcome monitoring;

• Culturally appropriate materials and methods to help clinicians explain to patients the benefits and limitations of antimicr obial drugs and the importance of appropriate use of these drugs; and

• Material that could be included in licensing, board certification, and credentialing

examinations.

Coordinators: CDC, FDA; Collaborators: DoD, DVA, HRSA, HCFA

Timeline: Initiated

3. Goal: Promote appropriate antimicrobial use through regulatory changes and public policy

actions.

a. Action Items

(27) Explore ways to integrate appropriate use information into antimicrobial package inserts and promotional materials, to provide such inform ation to patients with each prescription, and to provide clear guidance to industry to ensure that promotion of antimicrobials directed towards consumers encourages appropriate use and discourages inappropriate use. Coordinator: FDA; Collaborator: CDC

T imeline: Initiated

(28) Articulate factors that support the current approach of requiring prescription

- only dispensing for all systemic (i.e., nontopical) antimicrobial drugs used in clinical

medicine. Coordinator: FDA; Collaborator: CDC Timeline: Begin w ithin one to two years

(29) Periodically review and update antimicrobial drug susceptibility information included in drug labeling, with input from stakeholders and other experts, e.g., the National23 Committee for Clinical Laboratory Standards (NCCLS) and CDC.
Coordinator: FDA Timeline: Begin within one to two years

(30) Convene an advisory panel or other expert group involving stakeholders and
partners b to consider issues related to resistant pathogens that cause serious

infections for which available tr eatment options are very limited or nonexistent.

Issues include:

• Criteria for designating such drug

- pathogen combinations;

• Compiling and updating a list of such drug

- pathogen combinations;

• Recommendations for diagnosis and management of patients with susp ected or documented infection, including where appropriate that selected important drugs be preferentially used for the treatment of conditions associated with organisms that are resistant to other drugs;

• Publicizing and facilitating access to clinical tri als or compassionate use of investigational therapies;

• Recommendations for preventing infection transmission;

• Recommendations for performance and reporting of susceptibility test results for selected important drugs by clinical laboratories including possi bly that they be reported to clinicians only on request if an organism is sensitive to other appropriate drugs;

• Monitoring the use of selected important drugs, with consideration of changes in product labeling by FDA and in recommendations for use if incre ased resistance is detected; and

• Labeling by FDA of selected important drugs with the recommendation that they be preferentially used for the treatment of conditions associated with organisms that are resistant to other drugs. (Related Action Item: This item will also be considered in conjunction with Product Development #80.) Coordinators: FDA, CDC Timeline: Begin within one to two years

(31) Convene a working group to examine the impact of federal reimbursement policies for home parenteral antimi crobial treatment, appropriate antimicrobial use, and appropriate use of antimicrobial susceptibility testing. Where needed, the working group will make recommendations for modifying these policies. Coordinator: HCFA; Collaborators: CDC, HRSA

Timeline: Be gin within one to two years

(32) Develop and submit measures for appropriate antimicrobial use to the National Committee for Quality Assurance for inclusion in Health Plan Employer Data and Information Set (HEDIS), which provides comparative data on manag ed care organizations.24 Coordinator: CDC; Collaborator: HCFA

Timeline: Initiated

B. Issue: Improved diagnostic practices can enhance antimicrobial use and patient care.

1. Goal: Identify and promote the widespread use of diagnostic testing and reporting

s trategies that effectively facilitate appropriate use of antimicrobial drugs in routine practice.

a. Action Items

(33) Evaluate the potential impact of improved diagnostic tests, including rapid point

- of

care tests on antimicrobial drug use and patient care, and assess their financial implications. Take into account tests that distinguish between bacterial and viral infections, tests that identify resistant pathogens, and tests that distinguish common

clinical entities such as bacterial sinusitis and ac ute bacterial otitis media from

illnesses with similar manifestations for which antimicrobials are not beneficial. (Related Action Item: Research #76) Coordinators: CDC, FDA, NIH; Collaborators: DVA, DoD

, Timeline: Begin within one to two years

(34) Ide ntify economic and other barriers in the health care system (e.g., reimbursement policies by third

- party payers, managed care practices, cost considerations, empiric treatment recommendations, etc.) to diagnostic testing that promotes appropriate

use of an timicrobials. Develop recommendations that remove disincentives or promote incentives to such testing. Coordinator: HCFA; Collaborators: CDC, HRSA; AHRQ Timeline: Begin within three to five years

(35) In collaboration with professional societies, industr y, health departments, and other stakeholders and partners, b develop guidelines for clinicians and clinical microbiology laboratories that address:

• Appropriate specimen collection;

• Performance, interpretation, and reporting of antimicrobial (including

anti bacterial, antifungal, antiviral, and antiparasitic) susceptibility tests performed on clinical specimens; and

• Use of in

- office (point

- of

- care) tests for infection, including AR infections. Coordinator: CDC; Collaborators: FDA, DoD, DVA, HCFA, HRSA

Timelin e: Begin within three to five years

(36) In collaboration with professional societies, industry, health departments, and other stakeholders and partners, b develop guidelines that address the use of clinical25 microbiology laboratories for use by health care delivery organizations. The guidelines will:

• Promote access to clinical microbiology services by clinicians;

• Promote access to appropriate on

- site microbiology services in acute care facilities;

• Allow physicians to submit specimens to clinical laboratori es other than those designated by their health care delivery organization or the patient’s insurance company, with appropriate justifications; and

• Facilitate direct consultation between clinicians and laboratory personnel with appropriate expertise and aut hority. Coordinator: CDC; Collaborator: HCFA for bullet 2. Timeline: Begin within one to two years

(37) Promote the increased performance of direct examination of microbiological specimens (e.g., by Gram stain or other rapid method), in circumstances wher e appropriate, clinically relevant, and reliable information can be garnered, as a readily available point

- of

- care diagnostic test. This step will require working within the framework of the Clinical Laboratory Improvement Amendment (CLIA) regulations

and involving medical education and health care delivery organizations. Coordinator: CDC; Collaborator: HCFA Timeline: Begin within one to two years

C. Issue: Preventing infection transmission through improved infection control, behaviors that

prevent infect

ion (e.g., safe sexual practices), and use of vaccines can help prevent the spread of antimicrobial resistance.

1. Goal: Identify ways to reduce disease transmission in health care settings and in the

community.

a. Action Items

(38) Identify factors that promote transmission of drug

- resistant pathogens in health care facilities, in extended care facilities, and in community settings including daycare centers and in the community at large. These may include characteristics of the facilities and of the popu

lations that they serve. Coordinator: CDC; Collaborators: DVA, DoD

Timeline: Initiated26 (39) TOP PRIORITY ACTION ITEM

- Evaluate the effectiveness (including cost

effectiveness) of current and novel infection

- control practices for health care and

extende d care settings and in the community. Promote adherence to practices proven to be effective. Coordinator: CDC; Collaborators: DoD, DVA, HCFA, HRSA

Timeline: Initiated

(40) Evaluate the cost

- effectiveness and impact on patient care and drug resistance of medical devices that incorporate anti

- infective compounds to prevent infection (e.g.,

anti

- infective urinary catheters and prosthetic heart valves). Where appropriate (e.g., shown to be effective and not induce resistance), encourage the clinical use of

t hese devices. (Related Action Item: Product Development #82) Coordinator: CDC; Collaborators: AHRQ, DoD, DVA, FDA, HRSA,

HCFA Timeline: Begin within three to five years

(41) Encourage the development and implementation of clinical alternatives to those

i nvasive medical procedures and devices that increase the risk of infection in hospitals and other health care settings, e.g., substitution of transcutaneous monitoring of blood oxygen levels of indwelling catheters. Coordinator: CDC; Collaborators: FDA, DVA Timeline: Begin within three to five years

(42) Evaluate the benefits and risks of incorporating antimicrobial, disinfectant, or antiseptic chemicals into consumer products (e.g., soap, toys, kitchen utensils, clothes, paints, plastics, and film preservatives) and of applying disinfectants and sanitizers to hard, non

- porous surfaces such as food

- contact surfaces, hospital premises, bathrooms, etc. Consider whether they have any efficacy in reducing infection and/or may play a role in promoting d rug resistance. Coordinators: CDC, EPA; Collaborator: FDA Timeline; Initiated

2. Goal: Promote infection control through behavioral and educational interventions.

a. Action Items

(43) Conduct a public health campaign to promote hand hygiene and other hygienic practices, as well as other behaviors that prevent the transmission of infectious organisms, in collaboration with professional societies and stakeholders. This campaign may be coordinated with the public health education strategy to promote appropriate antimicrobial use described in Action Item #25: Prevention and Control. Components will include developing, evaluating, and facilitating the27 implementation of school

- based and other programs that promote hand hygiene and other behaviors that prevent infe ction, building on previous campaigns (e.g., American Society of Microbiology’s Operation Clean Hands). 27

Coordinator: CDC Timeline: Begin within one to two years

(44) Facilitate and support the activities of infection control programs in health care

set tings as a component of medical care. Promote infection control education at all stages of training and practice for all health care workers who have contact with patients. Coordinator: CDC; Collaborators: DVA, HCFA, DoD

, HRSA
Timeline: Initiated

(45) Su pport ongoing public health education campaigns on food safety, such as FDA and USDA’s Fight Bac program, 28 whose aims are to educate food producers, suppliers, retailers, and consumers about food safety practices that reduce foodborne infections (includin g AR infections). 29
Coordinators: USDA, CDC, FDA

Timeline: Initiated

(46) Educate the public about the merits and safety of irradiation as one tool to reduce

bacterial contamination of food.

Coordinator: CDC Timeline: Begin within one to two years

3. Goa l: Optimize the use of vaccines to prevent drug

- resistant infections and reduce

antibiotic use.

a. Action Items

(47) Support community

- based programs that promote and facilitate availability of

recommended vaccinations for adults and children.

Coordinator: CDC
Timeline: Initiated

(48) Identify vaccines useful in preventing drug

- resistant infections and reducing antimicrobial drug use, and evaluate novel methods for improving coverage with these vaccines. For example:

• Evaluate the risks and benefits of all owing certain vaccines for adults (e.g., for pneumococci and influenza virus) to be dispensed by pharmacists without prescription and

• Review and evaluate methods to promote administration of pneumococcal28 vaccines (e.g., offering vaccination when patients a re discharged from the hospital), and encourage the use of methods found to be effective. Coordinator: CDC; Collaborators: DVA, FDA, HCFA Timeline: Begin within three to five years

D. Issue: Prevention and control of drug resistance in agriculture and vet erinary medicine is important to promoting animal and plant health, as well as in preventing AR transmission to humans through the food supply or through contact with infected animals or the

environment.

1. Goal: Improve understanding of the risks and ben efits of antimicrobial use, and ways to prevent the emergence and spread of drug resistance, in agricultural and veterinary settings.

a. Action Items

(49) Evaluate the nature and magnitude of the impact of using various antimicrobial drugs as growth pro motants in different species, using current animal husbandry practices.

Use this information to assist in risk

- benefit assessments of such use. Coordinator: USDA; Collaborators: CDC, FDA Timeline: Begin within one to two years

(50) Conduct additional res earch to further define the effects of using various veterinary drugs on the emergence of resistant bacteria that infect or colonize food animals of different species, using various animal husbandry practices. Identify risk factors and preventive measures . Assess the associated risk of:

• Transmission of AR infections to humans;

• Clinical disease in humans; and

• Transfer of resistance factors from animal flora to human flora. Coordinators: CDC, USDA, FDA

Timeline: Initiated

(51) Conduct epidemiologic and la boratory studies to assess the risk of development and transfer of resistance related to the use of antimicrobial drugs in food and nonfood plants, and identify risk factors and potential preventive measures. Coordinator: USDA; Collaborators: CDC, FDA, EPA

Timeline: Initiated

(52) Develop rapid tests for inspecting fresh commodities like fruit for evidence of

contamination with bacteria that are resistant to antibiotics. Coordinator: USDA; Collaborators: EPA, FDA, CDC Timeline: Begin within one to two year s2 9 (53) Evaluate the effect of current food processing and distribution methods on the emergence and spread of drug

- resistant organisms. Coordinator: USDA; Collaborators: CDC, FDA Timeline: Begin within one to two years

(54) Identify and evaluate new food pasteurization strategies. Coordinator: USDA; Collaborators: FDA, CDC Timeline: Begin within three to five years

(55) Assess the risk of AR emergence and spread due to environmental contamination by antimicrobial drugs or by resistant bacteria in animal and human waste. Collect information on whether environmental contamination by antimicrobial drugs can lead to the development of resistance in bacteria that live in the soil or in water. (Related Action Item: Surveillance #19) Coordinators: USDA, CDC, EPA, FDA
Timeline: Initiated

(56) Assess the impact of antimicrobial use in companion animals (pets) on colonization and infection with drug

- resistant organisms in the animals and their human household

contacts.
Coordinator: CDC Timeline: Begin with in three to five years

2. Goal: Promote appropriate antimicrobial use in agricultural and veterinary settings.

a. Action Items

(57) Work with veterinary and agricultural communities to help educate users of veterinary and agricultural antimicrobials about AR issues, and promote the implementation and evaluation of guidelines that address these issues:

• Appropriate antimicrobial use in agricultural and veterinary settings;

• Performance and interpretation of antimicrobial susceptibility tests performed on speci mens from different species of animals; and

• Point

- of

- care tests for infection, including AR infections. Coordinators: USDA, CDC, FDA; Collaborator: EPA

Timeline: Initiated

(58) TOP PRIORITY ACTION ITEM

- In consultation with stakeholders, refine and imple ment the proposed FDA framework 30 for approving new antimicrobial drugs

for use in food

- animal production and, when appropriate, for re

- evaluating currently approved veterinary antimicrobial drugs. The proposed framework includes the following major steps :30 • Categorize antimicrobial drugs according to their importance in human medicine.

Timeline: Initiated

• Develop an approach to the establishment of thresholds for drug resistance in selected pathogens.

Timeline: Initiated

• Revise requirements for the industry ’s submission of drug use data.

Timeline: Initiated

• Develop procedures to assess microbial safety of antimicrobial drug use in

food

- producing animals.

Timeline: Initiated In support of the concepts articulated in the framework document:

• Conduct risk assess ments on the human health impact of using selected antimicrobials important in human medicine in food

- producing animals

Timeline: Initiated

• Initiate appropriate steps to address any unacceptable human health impact, if identified by the risk assessments, f or drugs categorized as being of critical importance in human medicine Timeline: Begin within one to two years

Coordinator: FDA

(59) Strongly encourage involvement of veterinarians in decisions regarding the use of systemic antimicrobial drugs in animals, regardless of the distribution system through which the drug is obtained (e.g., regardless of whether a prescription is required to obtain the drug). Coordinators: FDA, USDA

Timeline: Initiated

(60) Evaluate the potential impact of making all systemic ve terinary antimicrobial drugs available by prescription only. Coordinators: FDA, USDA Timeline: Begin within three to five years

(61) Convene an expert group to consider how to incorporate AR issues into regulations governing the registration and use of an timicrobials and antibiotic pesticides. Invite external experts, stakeholders, and the public to provide input.

Coordinator: EPA Timeline: Begin within one or two years31

E. Issue: Efforts to prevent and control AR emergence and spread must be comprehensi ve and multifaceted, involve a wide variety of nonfederal partners and the public, and become a part of routine practice nationwide.

1. Goal: Ensure input from nonfederal experts on federal efforts to combat antimicrobial

resistance.

a. Action Item

(62) Establish an ongoing mechanism to obtain periodic input from external experts on AR issues. This process will include ensuring input from stakeholders and partners b
(e.g., state and local health agencies, the private sector, and the public) in developing and reviewing federal efforts to address antimicrobial resistance. Coordinators: CDC, FDA, NIH; Collaborators: USDA, EPA, DoD, DVA, AHRQ, HRSA, HCFA Timeline: Begin within one to two years

2. Goal: Develop and evaluate comprehensive demonstration programs to prevent and

control AR.

a. Action Item

(63) TOP PRIORITY ACTION ITEM

- Support demonstration projects to evaluate comprehensive strategies that use multiple interventions to promote appropriate drug use and reduce infection rates. These projects will i nclude the following steps:

• Assess how interventions found effective in research studies can be applied routinely and most cost

- effectively on a large scale;

• Evaluate the use of these programs in health care systems (federal and nonfederal), in the communi ty, and in agricultural and veterinary settings; and

• Involve partnerships with local and state agencies, health care systems, professional societies, community organizations, schools, private industry, and the public. Coordinator: CDC; Collaborators: FDA, DVA, DoD, HRSA, HCFA

, Timeline: Initiated

3. Goal: Incorporate into routine clinical practice AR prevention strategies and programs that

have been found to be beneficial in research and demonstration projects.

a. Action Items

(64) Utilize f

ederal health care systems (e.g., DoD, DVA) as models for AR surveillance and prevention and control activities involving appropriate drug use, optimized32 diagnostic testing, infection control, and vaccination practice. Coordinators: CDC, DVA, DoD, HCFA, HR SA Timeline: Begin within three to five years

(65) For all health care systems for which federal funds are provided, identify and promote strategies to establish AR prevention and control activities as part of quality monitoring programs.

Coordinators: CD C, DVA, DoD, HCFA, HRSA
Timeline: Initiated

(66) Encourage nationally recognized accrediting agencies such as the National Committee for Quality Assurance (NCQA) and the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) to include accr editation standards that promote efforts to prevent and control AR, including appropriate antimicrobial use, infection control, vaccine use, and diagnostic testing. These standards may draw on the findings of existing data and demonstration programs

and A HRQ Evidence

- Based Practice Centers. Coordinator: CDC; Collaborators: HCFA, AHRQ Timeline: Begin within one to two years

III. Research

Antimicrobial resistance is among the most challenging problems in microbiology, clinical medicine, and public health. Antimicrobial resistance is not one problem, but an overarching term for an array of problems inherent in the evolution of microbes and influenced by antimicrobial use. Basic and clinical research provides the fundamental knowledge necessary to develop ap propriate responses to antimicrobial resistance emerging and spreading in hospitals, communities, farms, and the food supply. Major scientific accomplishments throughout the years have contributed much to the understanding of the fundamental biological pr ocesses of AR within microbes and the resulting impact on humans, animals, and the environment. This knowledge base provides us the opportunity to influence these processes and outcomes.

Because of its broad scope, the U.S. research community has a major contribution to make in meeting the goals the AR Task Force has set forth. The research and development of diagnostic tests, new antimicrobial agents, novel therapeutic products, and vaccines and other preventive approaches in response to AR is a multist ep process that begins with basic research discoveries and ends with the availability and use of a new product or implementation of a process. Along this pathway three areas need to be addressed: the identification of gaps and needs in the molecular and c ellular understanding of resistance, the infrastructure to support a robust research community, and a means for moving research findings into the development of new products.

The Interagency Task Force has worked with representatives from the public and p rivate sector to33

identify important research needs in microbial physiology, ecology, genetics and mechanisms of resistance. Existing gaps in knowledge and understanding should be addressed to augment the federal and private sector response to the overall problem. Efforts are underway to build and enhance the field of AR research, through increased focus, recognition, and collaboration. The aim is to develop a research infrastructure to support a critical mass of AR researchers who will interact, exchange information, and stimulate new discoveries. In order to move novel ideas arising in the research laboratory to useful products or approaches, support of the underlying infrastructure to study and test products and a mechanism to transition to industrial partners is necessary.

This effort will involve federal agencies that conduct, support and promote basic and clinical research in academia and industry and will involve prioritizing needs, identifying key opportunities, recruiting new investigators to the field, and making responsible use of resources to address AR problems.

A. Issue: Specific scientific gaps remain in the understanding of microbial physiology, ecology, genetics and mechanisms of resistance.

1.Goal: Identify gaps and address existing re search needs and identify new ones.

a. Action Items

(67) Additional research, including high risk and high payoff research in nontraditional fields, is needed to enhance the understanding and assess the impact of:

• Mechanisms of AR emergence, acquisition , spread, persistence, and decline, with special regard to multidrug resistant organisms;

• Emergence and transfer of resistance genes among microorganisms in vivo, including epidemiologic factors;

• Microbial ecology and the role of normal flora as a reposito ry of resistance factors, as well as the use of susceptible bacterial populations in the control of antimicrobial resistance;

• Effects of preventive, therapeutic, growth

- promoting agents and residues of agents in the environment on the microbiota of animals , plants, soil, and aquatic environments;

• Host factors and immune modulators (e.g., cytokines) in clinical resistance to treatments for opportunistic infections;

• The determinants of colonization and infection with drug

- resistant pathogens;

and

• Variations i

n antimicrobial use patterns that may affect the emergence and spread of resistance and the outcome of treatment, such as:

o Differences in duration and dosage in the administration of antimicrobial
agents;

o Prophylactic use of antimicrobial (including antiba cterial and antifungal)
agents;34 o Drug combinations used to treat resistant organisms; and

o The rotation (cycling) of antimicrobial drugs and other similar changes in selection and use of drug classes. Coordinator: NIH; Collaborators: CDC, FDA, DVA, USDA, EPA , DoD
Timeline: Initiated

(68) Conduct further government

- wide assessments with external input on the scope and composition of AR research to identify research opportunities. Coordinators: NIH, CDC, FDA, USDA; Collaborators: DoD, DVA, AHRQ, EPA, HCF

A

Tim eline: Initiated

B. Issue: The existing research infrastructure needs to ensure a critical mass of researchers in AR

and related fields.

1. Goal: Augment the scientific research infrastructure.

a. Action Items

(69) Work with the appropriate peer review s tructures to ensure that the requisite expertise is applied to the review process to facilitate funding of quality AR

research. Coordinators: NIH, DVA, FDA Timeline: Begin in one to two years

(70) TOP PRIORITY ACTION ITEM

- Provide to the research communi ty genomics and other powerful technologies to identify targets in critical areas for the development of new rapid diagnostics methodologies, novel therapeutics, and interventions to prevent the emergence and spread of resistant pathogens. Examples includ e tools such as microbial genome sequences, information on comparative genomics, DNA chip technology, informatics, and assistance in the application and use of these tools. Coordinator: NIH; Collaborators: DoD, USDA, FDA

Timeline: Initiated

(71) Encourage sharing of AR data between industry and the research community, including genomics and other technologies. Coordinator: NIH; Collaborators: DoD, USDA, FDA Timeline: Begin in three to five years

2. Goal: Develop a critical mass of researchers in AR.35 a. Acti on Items

(72) Bring new researchers into the field, by utilizing appropriate strategies such as training and research opportunities. Coordinator: NIH; Collaborators: CDC, FDA, USDA, DoD, DVA

Timeline: Initiated

(73) Organize conferences that address rese arch issues relating to AR.

Coordinator: NIH; Collaborators: CDC, USDA, FDA, DVA, DoD, AHRQ

Timeline: Initiated

C. Issue: Special efforts are needed to translate research findings into medically useful products

for human and agricultural/veterinary use, s uch as novel antimicrobial therapeutics, diagnostic tests, vaccines and other tools for preventing AR emergence and spread.

1. Goal: Address the governmental role in translating novel ideas into new clinically relevant

products, focusing on gaps not fille d by pharmaceutical industry and other
nongovernment groups.

a. Action Items

(74) Explore the need to encourage preclinical studies on the toxicology, pharmacokinetics, and pharmacodynamics of novel therapeutic agents for the treatment of multidrug

- resistan t pathogens and facilitate the transition of potential products from preclinical to clinical studies leading to development by industry of novel therapeutic agents. Coordinator: NIH; Collaborators: DoD, DVA, FDA, USDA Timeline: Begin within one to two year s

(75) TOP PRIORITY ACTION ITEM

- In consultation with academia and the private sector, identify and conduct human clinical studies addressing AR issues of public health significance that are unlikely to be studied in the private sector, such as:

• Novel th

erapies;

• Existing antimicrobials administered in treatment regimens and combinations that may not be included in approved indications and dosing schedules; and

• Other products and practices relevant to the control and treatment of

antimicrobial

- resistant pa

thogens including devices, diagnostics, antimicrobial soaps, disinfectants, etc. Coordinator: NIH; Collaborators: CDC, DVA, DoD, FDA Timeline: Begin within one to two years

2. Goal: Develop rapid, inexpensive, point

- of

- care diagnostic methods to facilitat e36 appropriate use of antimicrobials.

a. Action Item

(76) TOP PRIORITY ACTION ITEM

- Identify, develop, test, and evaluate new rapid diagnostic methods for human and veterinary uses with partners including academia and the private sector. Such methods shoul d be accurate, affordable, and easily implemented in routine clinical settings and may include:

• Tests for resistance genes that are associated with drug resistance, including nonculture specimens;

• Rapid point

- of

- care diagnostics for patients with viral res piratory infections and clinical syndromes such as otitis media, sinusitis, and pneumonia; and

• Rapid methods for detecting drug resistance among fungi, parasites, viruses, and mycobacteria. Coordinators: NIH, FDA; Collaborators: DoD, USDA, CDC, AHRQ, DVA

T imeline: Initiated

3. Goal: Develop new products and strategies to prevent and treat colonization and infection

with resistant organisms in patients, prevent transmission of resistant infections in the community, and prevent AR emergence

a. Action Items

(7 7) TOP PRIORITY ACTION ITEM

- Encourage basic and clinical research in support of the development and appropriate use of vaccines in human and veterinary medicine in partnership with academia and the private sector. Vaccines

are needed to:

• Prevent viral i

nfections that predispose patients to and are difficult to differentiate from bacterial infection and are presumptively treated with antibacterial agents (e.g., influenza virus);

• Prevent colonization, infection, and transmission of resistant organisms suc h as enterococci and staphylococci; and

• Prevent common bacterial infections (such as S. pneumoniae , nontypable Haemophilus influenzae) to reduce antibacterial use.

Coordinators: NIH, FDA; Collaborators: CDC, DoD, DVA, USDA

Timeline: Initiated

(78) Encour age basic and clinical research in support of novel approaches to preventing or treating infections with resistant organisms that occur in humans and animals by partnering with academia and the private sector. Novel approaches may include:

• Bacteriophage therapy;

• Active (vaccine) and passive (antibody, hyperimmune globulin) immunization;37 • Host

- derived antimicrobial agents;

• Nonantibiotic antimicrobials and nonchemical approaches with broad or nonspecific anti

- infective activities (e.g., defending and nonspec ific immunostimulants, such as defensins, ribozymes, etc.); and

• Microbial ecology (probiotics, direct fed microbials, etc.). Coordinator: NIH; Collaborators: DoD, DVA, FDA, USDA, CDC

Timeline: Initiated

IV. Product Development

New products are not being developed rapidly enough to address increasing microbial resistance. Needed products include not only new classes of antimicrobials able to kill otherwise resistant organisms, but also vaccines and anti

- infective devices with the potential to prevent infe ctions as well as improved diagnostic tools to aid in appropriate use of therapeutics. With respect to antimicrobial drugs, each new agent represents a major investment by a pharmaceutical company, which must shepherd the product through pre

- clinical stud ies and clinical testing, followed by large and expensive clinical trials. Pharmaceutical companies may be reluctant to invest extensive resources in the development of drugs, such as those antimicrobials targeted to resistant organisms, which are often g iven for short time periods to small numbers of patients. Manufacturers are similarly concerned that appropriate use policies may limit sales and profits. On the other hand, when a drug is used widely, allowing recovery of costs and profitability, resist

ance may develop more rapidly and shorten the useful life of the drug.

Due to these economic realities

–as well as to scientific limitations and a lag in the perception of a need for new agents

–very few novel antimicrobial drugs have reached the market for several years. A major aim of this interagency effort is to work with the private sector to explore and test innovative ways to address these issues. Approaches to be considered include providing incentives (and overcoming disincentives) to promote and assist the development of important products to address AR.

Product development is also a very important issue for veterinary medicine and agriculture. U.S. agencies and private sector partners must intensify efforts to encourage the development and use of veterinary drugs and agricultural practices that are unlikely to stimulate resistance to important human drugs or spread resistant pathogens to humans. Again, increased attention also needs to be turned to strategies to prevent infections of animal s (e.g., vaccines, changes in husbandry) and to the improved use of existing and new products.

A. Issue: Researchers and drug manufacturers need to be better informed of current and

projected gaps in the arsenal of antimicrobial drugs, vaccines, and diagn ostics and of potential markets for these products.

1. Goal: Provide a systematic assessment of the current status and projected future needs for

AR products.38 a. Action Item

(79) TOP PRIORITY ACTION ITEM

- Create an Interagency AR Product Development Work

ing Group to identify and publicize priority public health needs in human and animal medicine for new AR products (e.g., innovative drugs, targeted spectrum antibiotics, point

- of

- care diagnostics, vaccines and other biologics, anti

infective medical device s, and disinfectants). The Working Group will take these
steps:

• Obtain input from stakeholders, including pharmaceutical companies, physicians, epidemiologists, and microbiologists, on which products are needed;

• Involve experts in the nonmedical disciplin es (e.g., engineering and remote sensing, etc.);

• Model future resistance trends, product needs, and potential markets (particularly for novel and narrow spectrum uses), taking into account AR surveillance data and numbers of patients at high risk of develo ping drug resistant infections (e.g., increases in immunocompromised patients);

• Evaluate current market incentives for the development of priority AR products (Related Action Item: Product Development #80);

• Reassess AR product priorities on a regular basis ;

• Evaluate the availability of currently approved, critical products where shortages or potential for shortages exists and develop an approach to ensure that the supply of such products is adequate to meet public health needs; and

• Communicate the informat ion and priorities developed by the Workgroup to inform and allow coordination with planning and action efforts in research, prevention and control, and product development. Coordinators: FDA, USDA, CDC; Collaborators: NIH, AHRQ Timeline: Begin within one to two years

B. Issue: Existing market incentives and regulatory processes may be insufficient to stimulate the

development of certain priority AR products while fostering their appropriate use.

1. Goal: Investigate and act upon potential approaches for stimulating and speeding the entire

AR product development process, from drug discovery through licensing.

a. Action Items39 (80) TOP PRIORITY ACTION ITEM

- Identify ways (e.g. financial and/or other incentives or investments) to promote the development and/ or appropriate use of priority AR products, such as novel compounds and approaches, for human and veterinary medicine for which market incentives are inadequate.

• This process should include consultation with outside stakeholders, economic consultants, and the AR Product Development Working Group (Related Action Item: Product Development #79).

• All such proposals will require careful economic modeling and analysis. New approaches should be used on a trial basis for appropriate time periods and the

costs and benefits of incentives used in these pilot programs should be monitored to assess the return on the public investment.

• Similar incentives should be explored for ensuring adequate availability of existing products that meet critical public health needs but for which market incentives are inadequate to assure supply. (Related Action Item: Product Development #79). Coordinators: FDA, CDC; Collaborators: USDA, AHRQ Timeline: Begin within one to two years

(81) Consider, in consultation with academia and indust ry, whether government has a constructive role to play in discovery of drugs and other products targeted to address areas where market incentives are limited and unmet needs exist (e.g., novel antimicrobial drugs targeted to specific resistant organisms). (Related Action Items: Research Issue B)

• Such a role could utilize intramural, extramural or partnership type mechanisms. Products developed under such mechanisms could be licensed commercially either with or without specific stipulations regarding use. Coordinator: NIH; Collaborators: USDA, FDA, CDC Timeline: Begin within three to five years

(82) Continue ongoing approaches that streamline the regulatory process, including clinical trials and enhanced pre

- clinical studies (e.g., use of pharmacokinetics , and pharmacodynamics data) to help bring AR products (including drugs, vaccines, diagnostics and devices) to market as efficiently and rapidly as possible, while still assuring their safety and efficacy.

• This approach might involve use of an expedited pr ocess in which certain drugs are considered for approval, in accordance with Subpart E of the Investigational New Drug (IND) regulations. It might also involve defining new surrogate endpoints that indicate a meaningful response benefit over existing trea tments for particular infections (e.g., HIV

- 1 RNA viral loads or CD4 counts as surrogate markers in the treatment of HIV/AIDS), in accordance with Subpart H of New Drug Application (NDA) regulations.

• In the case of approvals for anti

- infective medical devi ces, AR concerns will be40 addressed during the pre

- and post

- licensing review, to ensure that these products reduce infection without engendering significant resistance.

• For products specifically targeted to serious or life

- threatening AR infections,

for whi ch there are few therapeutic alternatives, develop approaches for more focused development programs that would streamline product availability. This should be done in consultation with all of the stakeholders in the process. Coordinator: FDA; Collaborato r: USDA
Timeline: Initiated

C. Issue: The development and use of antimicrobial drugs and related products in agriculture and

veterinary medicine should be optimized to reduce the development and transfer of resistance to pathogens that can infect humans.

1. Goal: Promote the development and use of new and existing AR products that reduce the

risk of the development and transfer of antimicrobial resistance to humans, as well as new approaches to reducing agricultural and veterinary use of antimicrobial

dru gs.

a. Action Items

(83) In consultation with stakeholders and expert consultants, identify ways to promote the development of new and alternative veterinary treatments and the improved use of existing therapies that are unlikely to stimulate resistance to drugs in human medicine. This action will include consideration of the incentives and approaches listed in Action Items #80 (Product Development), #28 (Prevention and Control), and #78 (Research) and the implementation of pilot programs to stimulate the

d evelopment of priority products that meet critical animal health needs.

• Approaches for evaluation should include ways to improve and/or reduce the use of specific antimicrobial drugs, as well as ways to prevent infection, such as vaccines, changes in anim

al husbandry, and the use of competitive exclusion products (e.g., treatments that affect the intestinal flora of food animals). Coordinators: FDA, USDA, NIH, CDC Timeline: Begin within three to five years

(84) Streamline the regulatory and approval proce ss for veterinary antimicrobial drugs and related products that are unlikely, now or in the future, to result in transfer of

antimicrobial resistance to humans. Coordinators: FDA, USDA Timeline: Begin within three to five years41 References

1. Hofmann J, Cetron MS, Farley MM, et al. The prevalence of drug

- resistant Streptococcus pneumoniae in Atlanta. N Engl J Med. 1995;333:481

- 6.

2. Panlilio AL, Culver DH, Gaynes RP, et al. Methicillin

- resistant Staphylococcus aureus in U.S. hospitals, 1975

- 1991. Infect Control Hosp Epidemiol. 1992;13:582

- 6.

3. CDC. Four pediatric deaths from community

- acquired methicillin

- resistant Staphylococcus

aureus BMinnesota and North Dakota, 1997

- 1999. MMWR. 1999;48:707

- 10.

4. Gupta K, Scholes D, Stamm WE. Increasing prevalence of an timicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. JAMA. 1999;281:736

- 8.

5. Glynn MK, Bopp C, Dewitt W, et al. Emergence of multidrug

- resistant Salmonella enterica serotype typhimurium DT104 infections in the United Sta tes. N Engl J Med. 1998;338:1333

- 8.

6. Martone W. Spread of vancomycin

- resistant enterococci: why did it happen in the United States? Infect Control Hosp Epidemiol 1998;19:539

- 45.

7. Wiener J, Quinn JP, Bradford PA, et al. Multiple antibiotic

- resistant Klebs iella and

Escherichia coli in nursing homes. JAMA 1999;281:517

- 23.

8. CDC. Active Bacterial Core Surveillance, unpublished data 1999.

9. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin

- resistant S Staphylococcus aureus clinical str ain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997;40:135

- 136.

10. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus . N Engl J Med. 1999;340:493

- 501.

11. Pablos

- Mendez A, Raviglione MC, Las zlo A, et al. Global surveillance for antituberculous drug resistance, 1994

- 1997. N Engl J Med 1998;338:1641

- 9.

12. Fox KK, Knapp JS, Holmes KK, et al. Antimicrobial resistance in Neisseria gonorrhoeae in the United States, 1998

- 1994: the emergence of decr eased susceptibility to the fluoroquinolones. J Infect Dis 1997;175:1396

- 403.

13. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998;279:1977

- 83.42

14. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemotherapy 1995;39:1

- 8.

15. White NJ. Drug resistance in malaria. Br Med Bull 1998;54:703

- 15.

16. Adcock PM, Pastor P, Medley F, et al. Methicillin

- resistant Staphylococcus aureus in two

child care centers. J Infect Dis 1998;178:577

- 80.

17. U.S. Congress, Office of Technology Assessment, Impacts of Antibiotic

- Resistant Bacteria

, OTA

- H

- 629, Washington, DC: U.S. Government Printing Office, September 1995.

18. National Academy of Sciences, Institute of M edicine. Forum on Emerging Infections, Antimicrobial Resistance: Issues and Options [Workshop Report], Washington, DC, 1998.

19. American Society for Microbiology. Report of the ASM Task Force on Antibiotic Resistance, Washington, DC, 1995.

20. World Health Or

ganization. World Health Organization Report on Infectious Diseases 2000; Overcoming Antimicrobial Resistance. WHO/CDS/2000.2 Geneva 2000.

21. General Accounting Office, Antimicrobial Resistance: Data to assess public health threat from

resistant bacteria are

limited [GAO/HEHS/NSIAD/RCED

- 99

- 132], Washington, DC, April

1999.

22. General Accounting Office, Food Safety: The agricultural use of antibiotics and its implications for human health [GAO/RCED

- 99

- 74], Washington, DC, April 1999.

23. World Health Organization. Draft Global Strategy for the Containment of Antimicrobial Resistance. Available on the Internet at <http://www.who.int/emc/amr.html.

24. Centers for Disease Control. A national action plan to combat multidrug resistant tuberculosis. MMWR 1992;41 (RR

- 11).

25. D epartment of Health and Human Services. Development of a Public Health Action Plan to Combat Antimicrobial Resistance. Federal Register 1999;64:34558.

26. Department of Health and Human Services. Draft Public Health Action Plan to Combat

Antimicrobial Resist

ance. Federal Register 2000; 65:38832

- 3.

27. American Society for Microbiology. Clean Hands Campaign. Available on the Internet at

< http://www.washup.org/>.43

28. Partnership for Food Safety Education. Fight Bac! Available on the Internet at <http://www.fightbac.o rg/>.

29. Department of Agriculture. U.S. Government Food Safety for Farm to Table: A National

Food

- Safety Initiative, A Report to the President, Washington, DC, May 1997.

30. Food and Drug Administration. A Proposed Framework for Evaluating and Assuring the

H uman Safety of the Microbial Effects of Antimicrobial New Animal Drugs Intended for Use in

Food

- producing Animals, Rockville, MD, February 1999.

# Index to the Action Items

Terms below are listed according to the Action Items in which they may be found. These and other terms may also be found in the Executive Summary, Top Priority Action Items, and Introduction and Overview sections of the document.

accreditation 7, 66 Agency for Healthcare Research and Quality (AHRQ) coordinator 11, 16 collaborator 21, 22, 34, 40, 62, 66, 68, 73, 76, 79, 80 agriculture 5, 13, 83, 84 animal and plant health 19, 83 animal husbandry 50, 83 farms 17, 18
see als o food safety AHRQ see Agency for Healthcare Research and Quality American Society for Microbiology (ASM) 43 antimicrobial drugs availability of 5, 12, 47, 60, 79, 80, 82 discovery of 12, 80

- 82 stimulating resistance 20, 55, 83 gaps in the arsenal of drugs 5, 74, 75, 79 monitoring patterns of drug use 3, 4, 5, 22, 67
overuse and misuse of see appropriate use prescribing 22, 23, 59, 60 susceptibility of 3, 8

- 13, 29

- 31, 35, 37 antimicrobial resistance (AR) communities, spread of AR in 63, 78

emerge nce of 3, 4, 20, 50, 51, 53, 55, 67, 70, 83

- 84 nonfederal partners 62, 63 the public, and 61

- 63 spread of 53, 55, 67, 70 appropriate use of antimicrobial drugs 21

- 27, 31

- 34, 43, 57, 59, 63, 64, 66, 76, 80 promotion of 21, 22, 25, 26, 43, 63, 66, 80
A SM see American Society for Microbiology bacteria 17, 18, 20, 33, 35, 46, 50, 52 behavioral change 24

- 26, 43
behavioral interventions see behavioral change
CDC see Centers for Disease Control and Prevention
Centers for Disease Control and Prevention (CDC)
coordinator 1

- 26, 30

- 33, 35

- 48, 50, 55

- 57, 62

- 66, 68, 79, 80, 83 collaborator 27, 28, 34, 49, 51

- 54, 67, 72, 73, 75

- 78,
81
CLIA see Clinical Laboratory Improvement Amendments
clinical devices see medical devices and procedures Clinical Laboratory

Improvement Amendments (CLIA) 37 clinical trials 30, 35, 74, 75, 82 competitive exclusion products 83 computer

- assisted decision support 24, 26 confidentiality 3, 5

consumer groups see consumers consumer products 5, 42 consumers 27, 45
contaminati on bacterial 46, 52 environmental 19, 55
see also environmental impact core capacities 13, 14

cross

- infection see infection daycare centers 25, 38 demonstration projects 2, 63 Department of Defense (DoD) coordinator 64, 65 collaborator 2, 3, 5, 2 1, 22, 24, 26, 33, 35, 38

- 40, 44, 62, 63, 67, 68, 70

- 78 Department of Veterans Affairs (DVA) coordinator 64, 65, 69 collaborator 2, 3, 5, 21, 22, 24, 26, 33, 35, 38

- 41, 44, 48, 62, 63, 67, 68, 72

- 78 detection and reporting see surveillance diagnosis 4, 5, 30 diagnostic tests and testing 13, 14, 33, 34, 37, 64, 66, 70, 75, 76, 79, 82
disinfectants 42, 75, 79
DoD see Department of Defense drugs see antimicrobial drugs
DVA see Department of Veterans Affairs economics 11, 34, 80
electronic surveillan

ce see surveillance environmental impact 67
see also contamination environmental Environmental Protection Agency (EPA) coordinator 1, 3, 19, 20, 42, 55, 61 collaborator 5, 51, 52, 57, 62, 67, 68
EPA see Environmental Protection Agency epidemiology 1 0, 51, 67, 79 extended care facilities 21, 38, 39
FDA see Food and Drug Administration
flu see influenza Food and Drug Administration (FDA)
coordinator 1

- 6, 9, 10, 13, 15, 17, 18, 23, 25

- 30, 33, 45, 50, 55, 57

- 60, 62, 68, 69, 72, 73, 76, 77, 79, 80,
82

- 84 collaborator 2, 3, 21, 22, 35, 40

- 42, 48, 49, 51

- 54, 63, 67, 70, 71, 74, 75, 78, 81 food safety 6, 17, 45, 46, 49

- 51, 53, 54, 58, 83 fungi 35, 67, 76 genetics see microbial genes and microbial genomics growth promotants 49 guidelines, clinical 26 , 35
HCFA see Healthcare Financing Administration health care delivery 6, 7, 16, 22, 34, 36

- 42, 44, 63

- 65 hospitals 21, 22, 24, 41, 48 managed care 32, 34 state and local health agencies 13, 14, 62, 63 Healthcare Financing Administration (HCFA)
coordi nator 7, 10, 11, 15, 31, 34, 64, 65 collaborator 2, 3, 8, 22, 24

- 26, 32, 35

- 37, 39, 40, 44, 48, 62, 63, 66, 68 Health Plan Employer Data and Information Set (HEDIS)
32 Health Resources and Services Administration (HRSA) coordinator 11, 64, 65
collabora tor 3, 26, 31, 34, 35, 39, 40, 44, 62, 63HEDIS see Health Plan Employer Data and Information Set

HIV/AIDS 82
host factors 67
HRSA see Health Resources and Services Administration hygienic practices 43
immunization see vaccine
infection control 39, 44, 64, 66, 75 transmission 17, 30, 38, 43, 50, 77 influenza 48, 77
insurance 36
JCAHO see Joint Commission on Accreditation of Healthcare Organizations
Joint Commission on Accreditation of Healthcare Organizations (JCAHO) 66 labeling 4, 9, 29, 30
l aboratories 2

- 4, 8

- 10, 12

- 14, 29, 30, 35, 36, 51 market incentives 34, 80, 81, 83 medical devices and procedures 40, 70
Medicare 24
microbial ecology 67, 78 genes 67, 76 genomics 70 microbiologists 79 microbiology 35, 37, 43
mold see mould
mould 10 National Committee for Clinical Laboratory Standards (NCCLS) 10, 29 National Committee for Quality Assurance (NCQA) 66 National Institutes of Health (NIH) coordinator 10, 33, 62, 67

- 78, 81, 83 collaborator 4, 79
NCCLS see National Committee for C linical Laboratory
Standards NCQA see National Committee for Quality Assurance
NIH see National Institutes of Health nongovernment surveillance see surveillance

outcomes see patient outcomes outpatient 21 package inserts 27 parasites 10, 35, 76 pati ent outcomes 5, 16, 22, 24, 26, 67 Peer Review Organizations (PROs) 24 pesticide use 20, 61 pharmaceutical companies 74, 79 pharmacies 6, 48 pharmacodynamics 74, 82 pharmacokinetics 74, 82 pilot programs 80, 83 pilot studies 2, 19

pre

- clinical s tudies 74, 82 Prevention and Control (Focus Area II) 21

- 66 Product Development (Focus Area IV) 79

- 84 products, new antimicrobials 58, 74, 75, 78, 79, 82

- 84 vaccines 77, 78, 82, 83 proficiency testing programs 8
PROs see Peer Review Organizations pub lic health education campaign 25, 43, 45, 46 quality assurance 7, 14, 26 reimbursement 31, 34 regulations 61, 82 regulatory process 82, 84 reporting see Surveillance (Focus Area I) Research (Focus Area III) 67

- 78
resistance mechanisms 67
Surveillan

ce (Focus Area I) 1

- 20
surveillance
electronic 3 national plan 2 nongovernment 2 susceptibility data see antimicrobial drugs susceptibility Top Priority Action Items 2, 5, 25, 26, 39, 58, 63, 70, 75

- 77, 79, 80 training programs 8, 26, 44, 72

treatm ent, novel 48, 70, 74, 75, 78

- 81
USDA see U.S. Department of Agriculture U.S. Department of Agriculture (USDA)
coordinator 1

- 6, 10, 13

- 15, 17

- 20, 45, 49

- 55, 57, 59, 60, 68, 79, 83, 84 collaborator 2, 3, 25, 62, 63, 67, 70

- 74, 76

- 78, 80

- 82
vaccination see vaccine vaccine 47, 48, 64, 66, 77, 78, 79, 82, 83 veterinary medicine 2, 3, 5, 6, 13

- 15, 49

- 61, 63, 76, 77, 80, 83, 84
viral infection see viruses viruses 10, 33, 35, 76, 77, 82 yeast 10